Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis.
<h4>Background</h4>The therapeutic role of antifibrotic therapy has been well-established in idiopathic pulmonary fibrosis (IPF). However, its efficacy and safety for interstitial lung diseases (ILDs) other than IPF are not fully understood.<h4>Methods</h4>We updated a system...
Saved in:
| Main Authors: | Mei Yang, Yuying Tan, Ting Yang, Dan Xu, Mei Chen, Lei Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0318877 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-Inflammatory Versus Antifibrotic Therapies for the Management of Rheumatoid Arthritis–Associated Interstitial Lung Disease: Protocol for a Systematic Review and Meta-Analysis
by: Sneh Sonaiya, et al.
Published: (2025-07-01) -
Korean Guidelines for the Diagnosis and Management of Interstitial Lung Disease: Other Forms of Interstitial Lung Disease
by: Hyung Koo Kang, et al.
Published: (2025-07-01) -
Impact of antifibrotics on post-COVID-19 lung sequelae
by: Yosri Mohamed Kamel Akl, et al.
Published: (2025-06-01) -
Interaction mechanism between blockchain and IPFS
by: Feng Yang, et al.
Published: (2023-07-01) -
Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database
by: Yasuhiro Kondoh, et al.
Published: (2025-05-01)